
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Category Reports Biotech
Tickers reports and analysis
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Biotech Radar July 13, 2026: Sanofi, Guardant Health and Pharvaris

Biotech Radar July 13, 2026 $SNY $GH $PHVS Three-name biotech watch Biotech Radar July 13, 2026: Sanofi ($SNY), Guardant Health ($GH) and Pharvaris ($PHVS) Three distinct healthcare setups define today’s watch: a first-of-its-kind oncology delivery approval, a competitive read-through in…
Biotech Radar — July 11, 2026: Chemomab, CervoMed and AtaiBeckley — $CMMB $CRVO $ATAI

Today’s radar compares three very different catalyst structures: Chemomab’s proposed merger with Scipher Medicine and shift toward AI-guided rheumatoid arthritis development, CervoMed’s completed Phase 2a enrollment in nonfluent variant primary progressive aphasia, and AtaiBeckley’s completion of dosing in the VLS-01 Phase 2b Elumina trial ahead of a Q4 2026 topline readout.
Biotech Radar — July 8, 2026: Vertex’s $10B Crinetics Deal, Seres’ Microbiome Signal and OKYO’s FDA Phase 3 Pathway ($CRNX, $MCRB, $OKYO)

Biotech radar: Vertex to acquire Crinetics ($CRNX) for ~$10B, Seres ($MCRB) posts an early 80% Day 15 SER-155 signal in checkpoint-inhibitor enterocolitis, and OKYO ($OKYO) moves urcosimod to Phase 3 NEPTUNE after FDA Type D feedback.
Biotech Radar: $VANI, $PHVS, $TOVX — Three Catalyst Stories From GLP-1 Implants to HAE and Pancreatic Cancer

Today’s radar is not built around one single theme. It is built around three very different biotech catalyst profiles: a small-cap GLP-1 implant narrative, a cleaner late-stage rare-disease regulatory story, and a highly speculative oncology microcap with a real but very early dosing question.
Biotech Radar — July 6, 2026: $PHVS, $AGEN, $IONS (FDA NDA Acceptance, MSS Colorectal Survival Data, Phase 3 Angelman Milestone)

Biotech radar for July 6, 2026: Pharvaris ($PHVS) FDA NDA acceptance with an April 2027 PDUFA date, Agenus ($AGEN) three-year BOT+BAL survival data in MSS colorectal cancer, and Ionis ($IONS) Phase 3 pivotal enrollment complete in Angelman syndrome.
Biotech Radar July 1, 2026: $CANF, $ABVX, $SXTP and $MODD Lead Today’s Catalyst Watch

Today’s biotech tape is not built around one single mega-cap headline. It is a classic catalyst radar session: one small oncology name with a fresh Phase 2a survival signal, one late-stage inflammatory disease story with a major Phase 3/NDA setup but financing pressure, one infectious-disease micro-cap tied to babesiosis development, and one diabetes medtech name moving from clearance into real-world use.
Biotech Radar — June 29, 2026: Ipsen-Kartos M&A, $CAPR’s FDA AdCom and $REPL’s RP1 Resubmission

The biotech calendar is entering a dense FDA-driven window, with three Nasdaq-listed names standing out for very different reasons: a renal-disease PDUFA decision watch, a rare-disease cell therapy advisory committee, and an oncology BLA resubmission that has put accelerated approval back in focus.
Russell 2026 Biotech Watchlist: $UNCY, $GALT, $SPRB, $OVID and the Small-Cap Health Care Additions to Watch

RUSSELL 2026 PRELIMINARY LIST 87 HEALTH CARE ADDITIONS BIOTECH FOCUS Russell 2026 Biotech Watchlist: $UNCY, $GALT, $SPRB, $OVID and the Small-Cap Health Care Additions to Watch The June 2026 Russell reconstitution becomes effective after the U.S. market close on June…
Biotech Radar – $DFTX $ABSI $NVCT – June 24, 2026

Phase 3 clinical data, analyst coverage and an international licensing deal: three real, verified catalysts across DFTX, ABSI and NVCT.
Oculis Holding AG (Nasdaq: $OCS): DIAMOND Phase 3 miss resets the story toward Privosegtor and Licaminlimab

After OCS-01 failed to meet the primary visual acuity endpoint in both DIAMOND Phase 3 trials for diabetic macular edema, Oculis is no longer a clean near-term DME filing story. The new setup is a cash-rich ophthalmology and neuro-ophthalmology pipeline reset, with Privosegtor and Licaminlimab now carrying the next real tests.
Primary endp
5 energy stocks under $2 billion to watch in march ( $PUMP $EGY $RNGR $GEOS $KLXE )

This article compares five U.S.-listed energy names below $2 billion in market value that could benefit, directly or indirectly, from a stronger oil tape, firmer field activity, or renewed investor appetite for smaller-cap energy exposure: ProPetro (PUMP), VAALCO Energy (EGY), Ranger Energy Services (RNGR), Geospace Technologies (GEOS) and KLX Energy Services (KLXE).
Taxing unrealised gains: why the Dutch “experiment

Taxing unrealised gains: why the Dutch “experiment” is a red line for investors A closer look at the Actual Return Box 3 proposal in the Netherlands, why a 36% tax on unrealised portfolio gains is structurally toxic, and what this…
WAR US–Israel vs Iran, 2026 Small & mid-cap potential “winners & losers”

Focus on factual developments of the last few days (Strait of Hormuz, tankers at anchor, oil spike) and on a sector-based watchlist – not on trying to predict the endgame of the conf
War in Iran 2026 – Geopolitics, Oil Shock Risk and Market Winners & Losers

An editorial look at what the new Iran–Israel–US conflict could mean for global power balances, for oil and shipping routes, and for the sectors and individual stocks that tend to benefit or suffer when the Middle East becomes the epicentre of risk.
EN
IT
AI in Biotech 2026 $RXRX $TEM $EXAI

Recursion, Tempus AI and Exscientia are three “pure-play” examples of what it really means to put artificial intelligence at the centre of a biotech business model. Used properly, AI can compress timelines, surface non-obvious biology and make better use of messy data. Used badly, it can amplify errors, burn cash faster and create stories the clinic will never confirm.
Top 10 Biotech Stocks to Watch in H2 2026 — PDUFA Dates & Catalysts

Ten US-listed small- and mid-cap biotech stocks with key H2 2026 catalysts, including PDUFA dates, FDA advisory committees and pivotal Phase 3 readouts. Exact dates are separated from company-guided windows; the original H1 2026 analysis remains available as a historical archive.
Cognition Therapeutics $CGTX

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative, small-molecule oligomer antagonists for age-related degenerative disorders of the central nervous system, primarily Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB).
ALVO Alvotech Feb 2026

Alvotech is not a typical development-stage biotech: it is a vertically integrated biosimilar platform that already generates hundreds of millions of dollars in revenue from launched products like AVT02 (adalimumab) and AVT04 (ustekinumab), while also running a crowded late-stage pipeline. The stock sits in that awkward middle ground between “early growth” and “heavy balance sheet”, with over 1B$ of debt but also positive adjusted EBITDA and operating profit in the latest 9-month period.
NMRA Neumora Therapeutics

Deep dive on Neumora Therapeutics (NMRA): navacaprant reset, NMRA-511 Alzheimer’s agitation data, M4 franchise and a 2026–2027 catalyst map for biotech run-up traders. Educational only, not investment advice.
SPACE & DEFENCE 2026

SIDU, ASTS, LUNR, ONDS and PL are not just “hot tickers”. Their satellites, landers, drones and imaging constellations are becoming building blocks of a Western answer to China’s dual-use space programs, Russia’s drone war and a world where infrastructure and data are contested every single day.



